Moscow: SiltaNews – News Desk
Researchers from the National Scientific and Technical Research Council of Argentina have achieved a breakthrough against glioblastoma, the most common malignant brain tumour in adults, characterised by high invasiveness and resistance to chemotherapy and radiotherapy, with a median survival of 9 months and a five-year rate of 7%.
The study, according to BRICSLat, a partner of TV BRICS, focuses on the Foxp3 protein, present in glioblastoma cells, which promotes cell migration and endothelial cell proliferation. Blocking Foxp3 using an experimental peptide called P60 improved the efficacy of chemotherapy and radiotherapy, reduced tumour cell viability and migration, and inhibited endothelial proliferation.
In animal models, the administration of P60 via an adenoviral vector eradicated the tumour and prolonged survival in one-third of treated mice, without neurotoxic effects. According to Marianela Candolfi, the study’s leader, Foxp3 represents a promising therapeutic target, although further research is needed before advancing to clinical trials in patients.